Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prabha Karnachi

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Chemical Information and Modeling|July 7, 2022
Prediction Accuracy of Production ADMET Models as a Function of Version: Activity Cliffs RuleRobert P Sheridan, J Chris Culberson, Elizabeth Joshi, et al.
Bioorganic & Medicinal Chemistry Letters|April 25, 2006
Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitorsYue-Mei Zhang, Xiaodong Fan, Bangping Xiang, et al.
Bioorganic & Medicinal Chemistry Letters|September 20, 2011
Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategyLawrence J Wilson, Bingbing Wang, Shyh-Ming Yang, et al.
Journal of Chemical Information and Modeling|March 25, 2020
Experimental Error, Kurtosis, Activity Cliffs, and Methodology: What Limits the Predictivity of Quantitative Structure-Activity Relationship Models?Robert P Sheridan, Prabha Karnachi, Matthew Tudor, et al.
Bioorganic & Medicinal Chemistry Letters|December 19, 2007
beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identificationShyh-Ming Yang, Robert H Scannevin, Bingbing Wang, et al.
Bioorganic & Medicinal Chemistry Letters|August 23, 2008
7-[1H-Indol-2-yl]-2,3-dihydro-isoindol-1-ones as dual Aurora-A/VEGF-R2 kinase inhibitors: design, synthesis, and biological activityTerry V Hughes, Stuart L Emanuel, Harold R O'Grady, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2007
beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituentsShyh-Ming Yang, Robert H Scannevin, Bingbing Wang, et al.
Bioorganic & Medicinal Chemistry Letters|November 6, 2007
1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic strokeYue-Mei Zhang, Xiaodong Fan, Devraj Chakaravarty, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2008
A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: design, synthesis, and biological activityTerry V Hughes, Guozhang Xu, Steven K Wetter, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical DevelopmentZhuming Zhang, Xin-Jie Chu, Jin-Jun Liu, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Chemical Information and Modeling|July 7, 2022
Prediction Accuracy of Production ADMET Models as a Function of Version: Activity Cliffs RuleRobert P Sheridan, J Chris Culberson, Elizabeth Joshi, et al.
Bioorganic & Medicinal Chemistry Letters|April 25, 2006
Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitorsYue-Mei Zhang, Xiaodong Fan, Bangping Xiang, et al.
Bioorganic & Medicinal Chemistry Letters|September 20, 2011
Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategyLawrence J Wilson, Bingbing Wang, Shyh-Ming Yang, et al.
Journal of Chemical Information and Modeling|March 25, 2020
Experimental Error, Kurtosis, Activity Cliffs, and Methodology: What Limits the Predictivity of Quantitative Structure-Activity Relationship Models?Robert P Sheridan, Prabha Karnachi, Matthew Tudor, et al.
Bioorganic & Medicinal Chemistry Letters|December 19, 2007
beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identificationShyh-Ming Yang, Robert H Scannevin, Bingbing Wang, et al.
Bioorganic & Medicinal Chemistry Letters|August 23, 2008
7-[1H-Indol-2-yl]-2,3-dihydro-isoindol-1-ones as dual Aurora-A/VEGF-R2 kinase inhibitors: design, synthesis, and biological activityTerry V Hughes, Stuart L Emanuel, Harold R O'Grady, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2007
beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituentsShyh-Ming Yang, Robert H Scannevin, Bingbing Wang, et al.
Bioorganic & Medicinal Chemistry Letters|November 6, 2007
1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic strokeYue-Mei Zhang, Xiaodong Fan, Devraj Chakaravarty, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2008
A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: design, synthesis, and biological activityTerry V Hughes, Guozhang Xu, Steven K Wetter, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical DevelopmentZhuming Zhang, Xin-Jie Chu, Jin-Jun Liu, et al.
Pageof 2